Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women

Journal of Menopausal Medicine
Mi Jung UmHyuk Jung

Abstract

To evaluate and compare the efficacy and safety of the combination of raloxifene and alendronate with those of monotherapies in elderly women with osteoporosis. Sixty-two postmenopausal women (mean age 63.5 ± 0.5 years) attending gynecologic osteoporosis clinics with established osteoporosis were randomly allocated to one of four treatment groups and monitored for 3 years. All patients enrolled in this study, including those in the control group (n = 14), received 1.0 g elemental calcium and 400 units of vitamin D per day. The raloxifene group (n = 16) received raloxifene 60 mg (Evista®) per day; alendronate group (n = 17) received low-dose (5 mg) alendronate with calcitriol 0.5 µg (Maxmarvil®) per day; and the combination therapy group (n = 15) received both raloxifene 60 mg and low-dose (5 mg) alendronate with calcitriol 0.5 µg. Bone mineral density (BMD) was measured in the lumbar spine and hip before and after 3 years of treatment. In patients who received the combined therapy, BMD increased in the lumbar spine and the hip by 7.2% (P<0.001) and 4.8% (P<0.001) at 3 years. For patients in the alendronate group, the increases were 6.7% (P<0.001) and 3.1% (P<0.01) respectively, for the raloxifene group, the increases were 4.36%...Continue Reading

References

Mar 12, 1998·Endocrine Reviews·H Fleisch
May 26, 1998·JAMA : the Journal of the American Medical Association·B W WalshP W Anderson
Jun 3, 1999·Drugs·B H Mitlak, F J Cohen
Jan 14, 2000·The Journal of Clinical Endocrinology and Metabolism·R D Wasnich, P D Miller
Mar 7, 2000·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·K G Faulkner
Jun 7, 2002·Lancet·Steven R Cummings, L Joseph Melton
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Aug 6, 2002·The Journal of Clinical Endocrinology and Metabolism·Pierre D DelmasUNKNOWN Mulitple Outcomes of Raloxifene Evaluation Investigators
Feb 25, 2009·Menopause International·Victor W Henderson
Jan 9, 2014·Annals of Clinical Biochemistry·Thinn Thinn Hlaing, Juliet E Compston
Jun 6, 2015·Journal of Menopausal Medicine·Hee-Jeong Choi
Aug 19, 2015·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·Barbara C SilvaWilliam D Leslie

❮ Previous
Next ❯

Citations

Apr 4, 2018·Menopause : the Journal of the North American Menopause Society·Vedhapriya Srinivasan, Mark G Martens
Sep 5, 2019·International Journal of Molecular Sciences·Hae Min Jeong, Dong Joon Kim
Jan 24, 2019·Journal of Menopausal Medicine·Imaneh KhorsandTalat Khadivzadeh

❮ Previous
Next ❯

Methods Mentioned

BETA
hormone replacement therapy
X-ray
enzyme-linked immunosorbent assays

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
A J DrakeK M Shakir
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
P D DelmasE A Nijland
© 2022 Meta ULC. All rights reserved